Sharon Yeatts to Dose-Response Relationship, Drug
This is a "connection" page, showing publications Sharon Yeatts has written about Dose-Response Relationship, Drug.
Connection Strength
0.686
-
A likelihood-based approach for computing the operating characteristics of the 3+3 phase I clinical trial design with extensions to other A+B designs. Clin Trials. 2015 Feb; 12(1):24-33.
Score: 0.368
-
An adaptive clinical trial design to identify the target dose of tenecteplase for treatment of acute pulmonary embolism. Clin Trials. 2022 Dec; 19(6):636-646.
Score: 0.157
-
Novel methodologic approaches to phase I, II, and III trials. Stroke. 2013 Jun; 44(6 Suppl 1):S116-8.
Score: 0.083
-
Optimal design for the precise estimation of an interaction threshold: the impact of exposure to a mixture of 18 polyhalogenated aromatic hydrocarbons. Risk Anal. 2012 Oct; 32(10):1784-97.
Score: 0.078